載入中
NASDAQHealthcareBiotechnology
最新資料
US$2.3887
−US$0.0513 · -2.10%
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
收盤時
US$2.3887
−US$0.0513 · -2.10%
盤後
US$2.39
+US$0.0013 · +0.05%
10月12日 下午4:10 ET
盤中時間採用ET。市場資料可能有所延遲。
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
日內區間
目前US$2.3887
52週區間
目前US$2.3887
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
47
合理估值
情緒
55
多空交錯
風險
74
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
日內區間
目前US$2.3887
52週區間
目前US$2.3887
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 1.7萬 USD | 2.3萬 USD | 8000 USD | 2.3萬 USD |
| 毛利 | — | −1.7萬 USD | −2.3萬 USD | −8000 USD | −2.3萬 USD |
| 研究與開發 | 2118.5萬 USD | 1411.7萬 USD | 1733.4萬 USD | 1508.3萬 USD | 921萬 USD |
| 銷售、一般及管理費用 | 1595.6萬 USD | 1350.4萬 USD | 1404.3萬 USD | 1260.8萬 USD | 1131.1萬 USD |
| 營業費用 | 3714.1萬 USD | 2762.1萬 USD | 3137.7萬 USD | 2769.1萬 USD | 2052.1萬 USD |
| 利息收入 | 237.7萬 USD | 405萬 USD | 434.3萬 USD | 87.7萬 USD | 6000 USD |
| 折舊和攤銷 | 1.6萬 USD | 1.7萬 USD | 2.3萬 USD | 8000 USD | 2.3萬 USD |
| 營業利益 | −3714.1萬 USD | −2762.1萬 USD | −3137.7萬 USD | −2769.1萬 USD | −2052.1萬 USD |
| 淨利 | −3477萬 USD | −2550.4萬 USD | −3009.4萬 USD | −2696萬 USD | −2060.6萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$42.50
上漲空間 1679.21%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
